Baird Boosts Price Target on Regeneron (REGN) as Survey Indicates Positive Eylea Momentum

October 4, 2012 12:54 PM EDT Send to a Friend
Get Alerts REGN Hot Sheet
Price: $366.13 -0.95%

Rating Summary:
    17 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 37 | Down: 17 | New: 30
Trade REGN Now!
Join SI Premium – FREE
Baird reiterated an Outperform rating Regeneron Pharma (NASDAQ: REGN) and raised its price target to $175.00 (from $150.00).

"We remain REGN buyers in front of the company's Q312 earnings report as new survey data indicates positive Eylea momentum continues. Given this feedback, we are raising our Eylea estimates once again to levels well ahead of current 2012 guidance and 2012-2015 consensus," said analyst Christopher J. Raymond.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $158.07 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Robert W Baird, Earnings

Add Your Comment